Abvc Biopharma (ABVC) Long-Term Debt Issuances (2010 - 2026)

Abvc Biopharma (ABVC) has 14 years of Long-Term Debt Issuances data on file, last reported at -$102023.0 in Q1 2026.

• Quarterly Long-Term Debt Issuances fell 320.17% year-over-year to -$102023.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350648.0 (up 105.72% YoY) and the FY2025 annual result came in at $499010.0, up 45.87% from the prior year.
• Long-Term Debt Issuances eased to -$102023.0 in Q1 2026, from $490000.0 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $3.2 million in Q1 2023 to a low of -$1.8 million in Q3 2023.
• A 4-year average of $42506.4 and a median of $46339.0 in 2025 frame the typical range for Long-Term Debt Issuances.
• Annual changes were most pronounced in 2025 — Long-Term Debt Issuances soared 287.47% — and 2026, when it tumbled 320.17%.
• Tracing ABVC's Long-Term Debt Issuances over 4 years: stood at -$1.5 million in 2023, then jumped by 108.22% to $126461.0 in 2024, then soared by 287.47% to $490000.0 in 2025, then sank by 120.82% to -$102023.0 in 2026.
• The last three Long-Term Debt Issuances figures came in at -$102023.0 (Q1 2026), $490000.0 (Q4 2025), and $53479.0 (Q3 2025), per Business Quant data.